Previous 10 | Next 10 |
home / stock / argnf / argnf news
2023-11-27 11:04:09 ET Summary argenx's Q3 earnings exceeded expectations, with Vyvgart sales beating by 11%, indicating strong market demand. The anticipated approval for Vyvgart in CIDP by H2 2024 suggests continued positive sales growth. argenx's robust cash position, incre...
VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration with local authorities across the region to enable broad access to VYVGART SC for eligible patients Amsterdam, The Netherl...
2023-11-05 10:45:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Global Advantage Fund lost 6.1% in Q3 2023, underperforming its benchmarks. ...
2023-11-05 05:45:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Fifth Avenue Growth Fund lost 3.5% in Q3, in line with benchmarks. Fundament...
2023-11-04 11:35:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund declined 6.98% in Q3 2023, underperforming the benchma...
2023-11-04 10:00:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Opportunity Fund fell 5.03% in Q3, slightly underperforming the broader market. ...
Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression (MSE) in generalized myasthenia gravis (gMG) Patients treated with VYVGART experienced consistent improvements ...
2023-10-31 15:32:10 ET argenx SE (ARGX) Q3 2023 Earnings Conference Call October 31, 2023, 08:30 AM ET Company Participants Beth DelGiacco - VP and Global Head, Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Karen Massey - COO ...
2023-10-31 02:16:01 ET More on Argenx SE argenx: Efgartigimod Is Not Just A Drug, A Cornerstone argenx: Three Important Milestones Reached In 2023, More To Come Immunovant drives OmniAb higher after data update; argenx slips Seeking Alpha’s Quant Ratin...
$329 million in third quarter global net product sales On track to submit VYVGART ® Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet Management to host conference call today at 1:30 pm CET (8:30 am ET) ...
News, Short Squeeze, Breakout and More Instantly...
Argen X NV Company Name:
ARGNF Stock Symbol:
OTCMKTS Market:
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) , w...
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in more than 30 years for patients with CIDP Third approved indication for VYVGART®...
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next wave of innovative pipeline candidates to be introduced highlighting long-term commi...